{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T20:15:35Z","timestamp":1776284135844,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Max-Delbr\u00fcck-Centrum f\u00fcr Molekulare Medizin in der Helmholtz-Gemeinschaft (MDC)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The optimal efficacy of xenogeneically generated proteins intended for application in humans requires that their own antigenicity be minimized. This necessary adaptation of antibodies to a humanized version poses challenges since modifications even distant from the binding sites can greatly influence antigen recognition and this is the primary feature that must be maintained during all modifications. Current strategies often rely on grafting and\/or randomization\/selection to arrive at a humanized variant retaining the binding properties of the original molecule. However, in terms of speed and efficiency, rationally directed approaches can be superior, provided the requisite structural information is available. We present here a humanization procedure based on the high-resolution X-ray structure of a chimaeric IgG against a marker for multiple myeloma. Based on in silico modelling of humanizing amino acid substitutions identified from sequence alignments, we devised a straightforward cloning procedure to rapidly evaluate the proposed sequence changes. Careful inspection of the structure allowed the identification of a potentially problematic amino acid change that indeed disrupted antigen binding. Subsequent optimization of the antigen binding loop sequences resulted in substantial recovery of binding affinity lost in the completely humanized antibody. X-ray structures of the humanized and optimized variants demonstrate that the antigen binding mode is preserved, with surprisingly few direct contacts to antibody atoms. These results underline the importance of structural information for the efficient optimization of protein therapeutics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key messages<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Structure-based humanization of an IgG against BCMA, a marker for Multiple Myeloma.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Identification of problematic mutations and unexpected modification sites.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Structures of the modified IgG-antigen complexes verified predictions.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Provision of humanized high-affinity IgGs against BCMA for therapeutic applications.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00109-024-02470-4","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T01:25:00Z","timestamp":1721870700000},"page":"1151-1161","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Structure-based humanization of a therapeutic antibody for multiple myeloma"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5696-9679","authenticated-orcid":false,"given":"Stephen F.","family":"Marino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6190-1414","authenticated-orcid":false,"given":"Oliver","family":"Daumke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,25]]},"reference":[{"key":"2470_CR1","doi-asserted-by":"publisher","first-page":"2191301","DOI":"10.1080\/19420862.2023.2191301","volume":"15","author":"KP Martin","year":"2023","unstructured":"Martin KP, Grimaldi C, Grempler R, Hansel S, Kumar S (2023) Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based therapeutics. MAbs 15:2191301. https:\/\/doi.org\/10.1080\/19420862.2023.2191301","journal-title":"MAbs"},{"key":"2470_CR2","doi-asserted-by":"publisher","unstructured":"Lo K-M, Leger O, Hock B. Antibody engineering. Microbiol Spectrum 2(1):AID-0007\u20132012 (2014). https:\/\/doi.org\/10.1128\/microbiolspec.AID-0007-12","DOI":"10.1128\/microbiolspec.AID-0007-12"},{"key":"2470_CR3","doi-asserted-by":"publisher","first-page":"6851","DOI":"10.1073\/pnas.81.21.6851","volume":"81","author":"SL Morrison","year":"1984","unstructured":"Morrison SL, Johnson MJ, Herzenberg LA, Ol VT (1984) Chimaeric human antibody molecules: mouse antigen-binding domains with human constant region domains. PNAS 81:6851\u20136855. https:\/\/doi.org\/10.1073\/pnas.81.21.6851","journal-title":"PNAS"},{"key":"2470_CR4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/312643a0","volume":"312","author":"GL Boulianne","year":"1984","unstructured":"Boulianne GL, Hozumi N, Shulman MJ (1984) Production of functional chimaeric mouse\/human antibody. Nature 312:643\u2013646. https:\/\/doi.org\/10.1038\/312643a0","journal-title":"Nature"},{"key":"2470_CR5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/314268a0","volume":"314","author":"MS Neuberger","year":"1985","unstructured":"Neuberger MS et al (1985) A hapten-specific chimaeric IgE antibody with human physiological effector function. Nature 314:268\u2013270. https:\/\/doi.org\/10.1038\/314268a0","journal-title":"Nature"},{"key":"2470_CR6","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/321522a0","volume":"321","author":"PT Jones","year":"1986","unstructured":"Jones PT, Dear PH, Foote J, Neuberger MS, Winter G (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321:522\u2013525. https:\/\/doi.org\/10.1038\/321522a0","journal-title":"Nature"},{"key":"2470_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ymeth.2005.01.003","volume":"36","author":"SVS Kashmiri","year":"2005","unstructured":"Kashmiri SVS, DePascalis R, Gonzales NR, Schlom J (2005) SDR grafting \u2013 a new approach to antibody humanization. Methods 36:25\u201334. https:\/\/doi.org\/10.1016\/j.ymeth.2005.01.003","journal-title":"Methods"},{"key":"2470_CR8","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nbt0994-899","volume":"12","author":"LS Jespers","year":"1994","unstructured":"Jespers LS, Roberts A, Mahler SM, Winter G, Hoogenboom HR (1994) Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Biotechnology 12:899\u2013903. https:\/\/doi.org\/10.1038\/nbt0994-899","journal-title":"Biotechnology"},{"key":"2470_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ymeth.2005.01.006","volume":"36","author":"J Osbourn","year":"2005","unstructured":"Osbourn J, Groves M, Vaughan T (2005) From rodent reagents to human therapeutics using antibody guided selection. Methods 36:61\u201368. https:\/\/doi.org\/10.1016\/j.ymeth.2005.01.006","journal-title":"Methods"},{"key":"2470_CR10","doi-asserted-by":"publisher","first-page":"32212","DOI":"10.1371\/journal.pone.0032212","volume":"7","author":"S Covaceuszach","year":"2012","unstructured":"Covaceuszach S, Marinelli S, Krastanova I, Ugolini G, Pavone F, Lamba D, Cattaneo A (2012) Single cycle structure-based humanization of an anti-nerve growth factor therapeutic antibody. PlosOne 7:32212. https:\/\/doi.org\/10.1371\/journal.pone.0032212","journal-title":"PlosOne"},{"key":"2470_CR11","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.3390\/cancers15082240","volume":"15","author":"LX Xing","year":"2023","unstructured":"Xing LX, Liu Y, Liu J (2023) Targeting BCMA in multiple myeloma: advances in antibody-drug conjugate therapy. Cancers 15:2240\u20132255. https:\/\/doi.org\/10.3390\/cancers15082240","journal-title":"Cancers"},{"key":"2470_CR12","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2217\/fon-2023-0270","volume":"19","author":"JG Berdeja","year":"2023","unstructured":"Berdeja JG et al (2023) Plain language summary of the CARITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma. Future Oncol 19:1235\u20131247. https:\/\/doi.org\/10.2217\/fon-2023-0270","journal-title":"Future Oncol"},{"key":"2470_CR13","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.tips.2023.05.006","volume":"44","author":"B Pati\u00f1o-Escobar","year":"2023","unstructured":"Pati\u00f1o-Escobar B, Talbot A, Wiita AP (2023) Overcoming proteasome inhibitor resistance in the immunotherapy era. Trends Pharmacol Sci 44:507\u2013518. https:\/\/doi.org\/10.1016\/j.tips.2023.05.006","journal-title":"Trends Pharmacol Sci"},{"key":"2470_CR14","doi-asserted-by":"publisher","first-page":"7276","DOI":"10.4049\/jimmunol.179.11.7276","volume":"179","author":"JR Darce","year":"2007","unstructured":"Darce JR, Arendt BK, Wu X, Jelinek DF (2007) Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol 179:7276\u20137286. https:\/\/doi.org\/10.4049\/jimmunol.179.11.7276","journal-title":"J Immunol"},{"key":"2470_CR15","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.4049\/jimmunol.180.6.3655","volume":"180","author":"MJ Benson","year":"2008","unstructured":"Benson MJ et al (2008) Cutting edge: the dependence of plasma cells and independence of memory cells on BAFF and APRIL. J Immunol 180:3655\u20133659. https:\/\/doi.org\/10.4049\/jimmunol.180.6.3655","journal-title":"J Immunol"},{"key":"2470_CR16","doi-asserted-by":"publisher","first-page":"890","DOI":"10.4049\/jimmunol.182.2.890","volume":"182","author":"KL Good","year":"2009","unstructured":"Good KL, Avery DT, Tangye SG (2009) Resting human memory B cells are intrinsically programmed for enhanced survival and responsiveness to diverse stimuli compared to na\u00efve B cells. J Immunol 182:890\u2013901. https:\/\/doi.org\/10.4049\/jimmunol.182.2.890","journal-title":"J Immunol"},{"key":"2470_CR17","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1016\/j.ymthe.2018.06.012","volume":"26","author":"J Bluhm","year":"2018","unstructured":"Bluhm J et al (2018) CAR T cells with enhanced sensitivity to B cell maturation antigen for the targeting of B cell non-Hodgkin\u2019s lymphoma and multiple myeloma. Mol Ther 26:1906\u20131920. https:\/\/doi.org\/10.1016\/j.ymthe.2018.06.012","journal-title":"Mol Ther"},{"key":"2470_CR18","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.molonc.2015.03.010","volume":"9","author":"F Oden","year":"2015","unstructured":"Oden F et al (2015) Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma. Mol Oncol 9:1348\u20131358. https:\/\/doi.org\/10.1016\/j.molonc.2015.03.010","journal-title":"Mol Oncol"},{"key":"2470_CR19","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"D60","author":"P Emsley","year":"2004","unstructured":"Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D60:2126\u20132132. https:\/\/doi.org\/10.1107\/S0907444904019158","journal-title":"Acta Crystallogr"},{"key":"2470_CR20","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1107\/S0907444909037822","volume":"65","author":"J Sanchez-Weatherby","year":"2009","unstructured":"Sanchez-Weatherby J et al (2009) Improving diffraction by humidity control: a novel device compatible with X-ray beamlines. Acta Cryst D 65:1237\u20131246. https:\/\/doi.org\/10.1107\/S0907444909037822","journal-title":"Acta Cryst D"},{"issue":"Pt 4","key":"2470_CR21","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy AJ et al (2007) Phaser crystallographic software. J Appl Crystallogr 40(Pt 4):658\u2013674. https:\/\/doi.org\/10.1107\/S0021889807021206","journal-title":"J Appl Crystallogr"},{"key":"2470_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"D66","author":"PD Adams","year":"2010","unstructured":"Adams PD et al (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Cryst D66:213\u2013221. https:\/\/doi.org\/10.1107\/S0907444909052925","journal-title":"Acta Cryst"},{"key":"2470_CR23","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1107\/S0907444904026460","volume":"60","author":"E Krissinel","year":"2004","unstructured":"Krissinel E, Henrick K (2004) Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr D60:2256\u20132268. https:\/\/doi.org\/10.1107\/S0907444904026460","journal-title":"Acta Crystallogr"},{"key":"2470_CR24","unstructured":"The PyMOL Molecular Graphics System, Version 1.2r3pre, Schr\u00f6dinger, LLC"},{"key":"2470_CR25","doi-asserted-by":"publisher","unstructured":"Ye J, Ma N, Madden TL, Ostell JM (2013) IgBLAST: an immunoglobulin variable domain sequence analysis tool. Nucleic Acids Res\u00a041(Web Server Issue):W34-W40. https:\/\/doi.org\/10.1093\/nar\/gkt382","DOI":"10.1093\/nar\/gkt382"},{"key":"2470_CR26","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.xphs.2019.10.051","volume":"109","author":"ME Alam","year":"2020","unstructured":"Alam ME et al (2020) Unique impacts of methionine oxidation, tryptophan oxidation, and asparagine deamidation on antibody stability and aggregation. J Pharma Sci 109:656\u2013669. https:\/\/doi.org\/10.1016\/j.xphs.2019.10.051","journal-title":"J Pharma Sci"},{"key":"2470_CR27","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.3390\/ijms22083952","volume":"22","author":"K Zheng","year":"2021","unstructured":"Zheng K et al (2021) Monoclonal antibody aggregation associated with free radical induced oxidation. Int J Mol Sci 22:3952\u20133967. https:\/\/doi.org\/10.3390\/ijms22083952","journal-title":"Int J Mol Sci"},{"key":"2470_CR28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.4161\/mabs.3.3.15608","volume":"3","author":"J Vlasak","year":"2011","unstructured":"Vlasak J, Ionescu R (2011) Fragmentation of monoclonal antibodies mAbs 3:253\u2013263. https:\/\/doi.org\/10.4161\/mabs.3.3.15608","journal-title":"Fragmentation of monoclonal antibodies mAbs"},{"key":"2470_CR29","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1002\/jps.20405","volume":"94","author":"AB Joshi","year":"2005","unstructured":"Joshi AB, Sawal M, Kearney WR, Kirsch LE (2005) Studies on the mechanism of aspartic acid cleavage and glutamine deamidation in the acidic degradation of glucagon. J Pharmaceut Sci 94:1912\u20131927. https:\/\/doi.org\/10.1002\/jps.20405","journal-title":"J Pharmaceut Sci"},{"key":"2470_CR30","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/j.jmb.2006.01.023","volume":"357","author":"RL Stanfield","year":"2006","unstructured":"Stanfield RL, Zemla A, Wilson IA, Rupp B (2006) Antibody elbow angles are influenced by their light chain class. J Mol Biol 357:1566\u20131574. https:\/\/doi.org\/10.1016\/j.jmb.2006.01.023","journal-title":"J Mol Biol"},{"key":"2470_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/protein\/gzad021","volume":"36","author":"VA Boron","year":"2023","unstructured":"Boron VA, Martin ACR (2023) abYpap: improvements to the prediction of antibody VH\/VL packing using gradient boosted regression. PEDS 36:1\u20138. https:\/\/doi.org\/10.1093\/protein\/gzad021","journal-title":"PEDS"},{"key":"2470_CR32","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/0022-2836(92)91010-m","volume":"224","author":"J Foote","year":"1992","unstructured":"Foote J, Winter G (1992) Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol 224:487\u2013499. https:\/\/doi.org\/10.1016\/0022-2836(92)91010-m","journal-title":"J Mol Biol"},{"key":"2470_CR33","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/prot.25964","volume":"88","author":"M Arslan","year":"2020","unstructured":"Arslan M, Karadag D, Kalyoncu S (2020) Conformational changes in a Vernier zone region: implications for antibody dual specificity. Proteins 88:1447\u20131457. https:\/\/doi.org\/10.1002\/prot.25964","journal-title":"Proteins"},{"key":"2470_CR34","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.2741\/2786","volume":"13","author":"JC Almagro","year":"2008","unstructured":"Almagro JC, Fransson J (2008) Humanization of antibodies. Front Biosci 13:1619\u20131633. https:\/\/doi.org\/10.2741\/2786","journal-title":"Front Biosci"},{"key":"2470_CR35","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1074\/jbc.M706190200","volume":"283","author":"K Makabe","year":"2008","unstructured":"Makabe K et al (2008) Thermodynamic consequences of mutations in vernier zone residues of a humanized anti-human epidermal growth factor receptor murine antibody, 528. J Biol Chem 283:1156\u20131166. https:\/\/doi.org\/10.1074\/jbc.M706190200","journal-title":"J Biol Chem"},{"key":"2470_CR36","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/02648725.2013.801235","volume":"29","author":"Y Safdari","year":"2013","unstructured":"Safdari Y, Farajnia S, Asgharzadeh M, Khalili M (2013) Antibody humanization methods \u2013 a review and update. Biotechnol Gen Engineer Rev 29:175\u2013186. https:\/\/doi.org\/10.1080\/02648725.2013.801235","journal-title":"Biotechnol Gen Engineer Rev"},{"key":"2470_CR37","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.dib.2015.12.023","volume":"6","author":"SF Marino","year":"2016","unstructured":"Marino SF, Olal D, Daumke O (2016) A complex water network contributes to high-affinity binding in an antibody-antigen interface. DiB 6:394\u2013397. https:\/\/doi.org\/10.1016\/j.dib.2015.12.023","journal-title":"DiB"},{"key":"2470_CR38","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1158\/1535-7163.MCT-20-0287","volume":"20","author":"V Figueroa-Vasquez","year":"2021","unstructured":"Figueroa-Vasquez V et al (2021) HDP-101, and anti-BCMA antibody-drug-conjugate, safely delivers amanitin to induce cell death in proliferating and resting multiple myeloma cells. Mol Cancer Therap 20:367\u2013378. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0287","journal-title":"Mol Cancer Therap"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-024-02470-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-024-02470-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-024-02470-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T23:43:45Z","timestamp":1724888625000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-024-02470-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,25]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["2470"],"URL":"https:\/\/doi.org\/10.1007\/s00109-024-02470-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.09.27.559758","asserted-by":"object"}]},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,25]]},"assertion":[{"value":"8 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SFM and OD are inventors on multiple pending and granted patents derived from the international patent applications PCT\/EP2013\/072857, PCT\/EP2015\/059562, and PCT\/EP2017\/063862 concerning J22.9-xi and variants.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}